9905292-0
IPDS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 417/04, 417/14, A61K 31/41 | A1

(11) International Publication Number: **WO 98/58929**

(43) International Publication Date: 30 December 1998 (30.12.98)

(21) International Application Number: PCT/EP98/04021

(22) International Filing Date: 22 June 1998 (22.06.98)

(30) Priority Data:
97201930.1 24 June 1997 (24.06.97) EP
(34) Countries for which the regional or international application was filed: DE et al.
60/052,194 10 July 1997 (10.07.97) US

(71) Applicant *(for all designated States except US)*: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B–2340 Beerse (BE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: STOKBROEKX, Raymond, Antoine [BE/BE]; Rode Kruisstraat 17, B–2340 Beerse (BE). CEUSTERS, Marc, André [BE/BE]; Bredestraat 18, B–3293 Diest (BE). VAN DER AA, Marcel, Jozef, Maria [BE/BE]; Patersstraat 155 bus 1, B–2300 Turnhout (BE). LUYCKX, Marcel, Gerebernus, Maria [BE/BE]; Eksterstraat 24, B–2440 Geel (BE). WILLEMS, Marc [BE/BE]; Merellaan 46, B–2350 Vosselaar (BE). TUMAN, Robert, W. [US/US]; 103 Homestead Court, Chalfont, PA 18914 (US).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ANGIOGENESIS INHIBITING THIADIAZOLYL PYRIDAZINE DERIVATIVES

(57) Abstract

This invention concerns compounds of formula (I), the *N*–oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein R^1 is hydrogen, C_{1-6}alkyl, C_{1-6}alkyloxy, C_{1-6}alkylthio, amino, mono– or di(C_{1-6}alkyl)amino, Ar^1, Ar^1–NH–, C_{3-6}cycloalkyl, hydroxymethyl or benzyloxymethyl; R^2 and R^3 are hydrogen, or taken together may form a bivalent radical of formula –CH=CH–CH=CH–;



(I)

R^4, R^5 and R^6 are each independently selected from hydrogen, halo, C_{1-6}alkyl, C_{1-6}alkyloxy, trifluoromethyl, nitro, amino, cyano, azido, C_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkylthio, C_{1-6}alkyloxycarbonyl or Het^1; or when R^4 and R^5 are adjacent to each other they may be taken together to form a radical of formula –CH=CH–CH=CH–; A is a bivalent radical of formula NR^7, NR^7–Alk^1–X–, NR^7–Alk^1–X–Alk^2–, O–Alk^1–X–, O–Alk^1–X–Alk^2– or S–Alk^1–X–; wherein X is a direct bond, –O–, –S–, C=O, –NR^8– or Het^2; R^7 is hydrogen, C_{1-6}alkyl or Ar^2methyl; R^8 is hydrogen, C_{1-6}alkyl or Ar^2methyl; Alk^1 is C_{1-6}alkanediyl; Alk^2 is C_{1-4}alkanediyl; Ar^1 and Ar^2 are optionally substituted phenyl; phenyl; Het^1 and Het^2 are optionally substituted heterocycles; having angiogenesis inhibiting activity; their preparation, compositions containing them and their use as a medicine.